Clinical Trial Data Sharing: Central Public-Private Portal May Expand Access
This article was originally published in The Pink Sheet Daily
J&J has gotten 25 requests for data through YODA project; BMJ study ranks GSK, J&J, Pfizer highest in making data publicly available and Gilead lowest.
You may also be interested in...
In what appears to be the most expansive policy to date on release of clinical trial data, J&J will use an existing outside group and will share full clinical study reports and patient-level data regardless of when the studies were conducted.
Revised North American trade deal touted as enabling Congress to address crisis of high drug prices; requirement for 10 years biologic exclusivity is removed and language to allow incentives for generics added.
US FDA's Pediatric Experts, Not Review Division, Should Have Final Say On Pediatric Trials, Former Official Says
Former Associate Commissioner Janice Soreth says views of pediatric experts should take precedence over those of division directors regarding pediatric trials.